10-Q: Dyne Therapeutics Advances DM1, DMD Programs; Secures Funding

Dyne Therapeutics reports positive clinical data for its lead programs, z-basivarsen and z-rostudirsen, while securing significant financing to extend its cash runway into Q3 2027.

Summary

• Net loss for the nine months ended September 30, 2025, was $334.3 million, an increase from $227.9 million for the same period in 2024.
• Cash, cash equivalents, and marketable securities totaled $791.9 million as of September 30, 2025, providing a projected cash runway into the third quarter of 2027.
• Z-basivarsen (DM1) received Breakthrough Therapy Designation from the FDA in June 2025 and reported positive long-term efficacy and safety data from the ACHIEVE trial, showing sustained improvements in myotonia (vHOT), muscle strength (QMT 20% improvement at 12 months), and functional endpoints.
• The registrational expansion cohort for the ACHIEVE trial (DM1) has been initiated, targeting 60 patients, with full enrollment planned for early Q2 2026 and data expected in Q1 2027, supporting a potential U.S. Accelerated Approval submission in early Q3 2027.
• Z-rostudirsen (DMD) received Breakthrough Therapy Designation from the FDA in August 2025 and Orphan Drug designation in Japan in September 2025.
• Positive long-term safety and efficacy data for z-rostudirsen (DMD) from the DELIVER trial demonstrated dose-dependent exon skipping, best-in-class dystrophin expression, and sustained functional improvements.
• Enrollment for the registrational expansion cohort of the DELIVER trial (DMD) was completed in March 2025 (32 participants), with data planned for December 2025 and a potential U.S. Accelerated Approval submission in Q2 2026.
• The company secured an initial $100.0 million tranche from a $275.0 million loan agreement with Hercules Capital, Inc., providing net proceeds of $98.8 million in June 2025.
• A follow-on public offering in July 2025 generated net proceeds of $215.8 million, and an at-the-market offering during the nine months ended September 30, 2025, yielded $140.6 million in net proceeds.
• Research and development expenses increased to $302.9 million for the nine months ended September 30, 2025, from $199.6 million in the prior year period, driven by higher manufacturing and clinical trial activity for z-basivarsen and z-rostudirsen.
• General and administrative expenses increased to $49.2 million for the nine months ended September 30, 2025, from $47.2 million in the prior year period, primarily due to increased headcount and professional fees.
• A master manufacturing services agreement was entered into in October 2025, committing at least $25.5 million in fees through March 2027 for product candidate components.

Sentiment

Score: 7

Explanation: The company demonstrated significant clinical progress with both lead candidates receiving Breakthrough Therapy Designations and reporting positive long-term data. Successful capital raises have strengthened liquidity and extended the cash runway. However, it remains a clinical-stage company with substantial ongoing losses and a clear need for future funding, which introduces inherent risks.

Positives

• Strong cash position of $791.9 million (cash, cash equivalents, and marketable securities) as of September 30, 2025, extending the cash runway into Q3 2027.
• Z-basivarsen (DM1) received Breakthrough Therapy Designation from the FDA in June 2025, potentially expediting its development and regulatory review.
• Positive long-term efficacy and safety data for z-basivarsen (DM1) from the ACHIEVE trial, showing robust and sustained improvements in myotonia (vHOT) and muscle strength (20% improvement at 12 months).
• Initiation of the registrational expansion cohort for the ACHIEVE trial (DM1) and planned full enrollment by early Q2 2026, with data expected in Q1 2027, supporting potential U.S. Accelerated Approval.
• Z-rostudirsen (DMD) received Breakthrough Therapy Designation from the FDA in August 2025, potentially expediting its development and regulatory review.
• Z-rostudirsen (DMD) received Orphan Drug designation in Japan in September 2025, which may provide market exclusivity benefits.
• Positive long-term safety and efficacy data for z-rostudirsen (DMD) from the DELIVER trial, demonstrating dose-dependent exon skipping, best-in-class dystrophin expression, and sustained functional improvements.
• Completion of enrollment for the registrational expansion cohort of the DELIVER trial (DMD) in March 2025, with data expected in December 2025, supporting potential U.S. Accelerated Approval.
• Successful capital raises through a follow-on public offering ($215.8 million net), an at-the-market offering ($140.6 million net), and an initial debt tranche ($98.8 million net) from Hercules Capital, Inc.

Negatives

• Net loss increased to $334.3 million for the nine months ended September 30, 2025, from $227.9 million in the prior year, reflecting a high burn rate.
• Research and development expenses significantly increased to $302.9 million for the nine months ended September 30, 2025, from $199.6 million in 2024.
• The company has incurred significant operating losses since inception and does not expect to generate product revenue until at least 2027, if ever.
• Reliance on third parties for manufacturing, research, preclinical, and clinical testing introduces risks of unsatisfactory performance or termination of engagements.
• The loan agreement with Hercules Capital, Inc. contains restrictive and financial covenants (Minimum Cash Covenant, Minimum Revenue Covenant) that may limit operating flexibility.
• Potential for dilution of stockholders' ownership interests from future equity offerings.
• Increased costs and management time are devoted to compliance initiatives as a public company, especially no longer being an emerging growth company or smaller reporting company.
• Interest expense of $3.0 million was incurred for the nine months ended September 30, 2025, due to the new loan agreement.
• Other expense, net, of $1.4 million for the nine months ended September 30, 2025, was due to net foreign currency losses.

Risks

• Will need substantial additional funding; inability to raise capital when needed could force delays, reductions, or elimination of product development programs or commercialization efforts.
• Product candidates are in varying stages of preclinical and clinical development, and commercialization is not expected until at least 2027, if ever, with significant delays possible.
• May encounter substantial delays in commencement, enrollment, or completion of clinical trials, and data may fail to demonstrate sufficient safety and efficacy.
• The FORCE platform approach to discovery and development is unproven, and efforts to develop product candidates may not be successful.
• The outcome of preclinical studies and initial data from earlier-stage clinical trials may not be predictive of final results or future clinical trials.
• Product candidates may cause undesirable side effects or have other unexpected adverse properties, delaying or preventing regulatory approval or limiting commercial potential.
• The loan agreement with Hercules contains restrictive and financial covenants that may limit operating flexibility, and failure to comply could result in a default.
• Reliance on third parties to conduct product manufacturing, research, preclinical, and clinical testing, with risks of unsatisfactory performance.
• Faces substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully.
• Rights to develop and commercialize certain product candidates are subject to third-party licenses; failure to comply with obligations could lead to loss of intellectual property rights.
• Inability to obtain, maintain, and defend patent and other intellectual property protection, or insufficient scope of protection, could allow competitors to commercialize similar products.
• Limited operating history may make it difficult to evaluate business success and future viability.
• Ability to utilize net operating loss carryforwards and certain other tax attributes may be subject to limitations (e.g., Section 382 ownership changes).
• May be required to repay outstanding indebtedness under the Loan Agreement if an event of default occurs.
• Expending limited resources on a particular program or candidate may lead to failure to capitalize on more profitable opportunities.
• Clinical trial and product liability lawsuits could divert resources, incur substantial liabilities, and limit commercialization.
• Dependence on single-source suppliers for components and materials, risking supply disruptions or price increases.
• Collaborations with third parties may not be successful, limiting market potential.
• Inability to establish sales, marketing, and distribution capabilities or agreements with third parties could hinder commercialization.
• Biologic product candidates may face competition sooner than anticipated due to biosimilar pathways.
• Failure to achieve market acceptance by physicians, patients, and third-party payers.
• Market opportunities for product candidates may be smaller than believed, adversely affecting revenue.
• Uncertainty regarding pricing and reimbursement for rare disease treatments.
• Subject to stringent privacy and information security laws (HIPAA, GDPR, CCPA, CPRA) and potential for significant fines and penalties for non-compliance.
• Risk of misconduct or improper activities by employees, principal investigators, consultants, and commercial partners.
• Laws and regulations governing international operations may preclude development/sales outside the U.S. or adversely impact business.
• Changes in U.S. trade policy (e.g., tariffs, executive orders on drug pricing) could adversely impact business.
• Disruptions at the FDA and other government agencies (funding cuts, personnel losses, regulatory reforms, government shutdowns) could hinder timely guidance and approval.
• Disclosure controls and procedures may not prevent or detect all errors or fraud.
• Operations or those of third parties might be affected by natural disasters, pandemics, or other catastrophic events.
• Volatility of common stock price.
• Executive officers, directors, and affiliates have significant influence over stockholder matters.
• Broad discretion in the use of cash, cash equivalents, and marketable securities.
• No anticipated cash dividends; capital appreciation is the sole source of gain for stockholders.
• Significant portion of outstanding shares may be sold, causing stock price drop.
• Increased costs and management time due to operating as a public company, especially no longer being an EGC or SRC.
• Provisions in corporate charter documents and Delaware law could make company acquisition more difficult.
• Designation of Delaware courts and federal district courts as sole forum for certain actions.
• Changes in patent law could diminish patent value.
• Claims challenging inventorship or ownership of intellectual property.

Future Outlook

The company expects to continue incurring significant operating losses for the foreseeable future, with expenses and capital expenditure requirements anticipated to increase substantially as product candidates advance through clinical trials and additional indications are pursued. Existing cash, cash equivalents, and marketable securities are projected to fund operations into Q3 2027. The company plans to initiate a Phase 3 clinical trial for z-basivarsen in Q1 2026 and anticipates a potential launch in Q1 2028, assuming favorable data and FDA approval. Data from the DELIVER trial's registrational expansion cohort is expected in December 2025, with a potential U.S. Accelerated Approval submission in Q2 2026. Substantial additional funding will be required through equity offerings, debt financings, collaborations, strategic alliances, and/or licensing arrangements to support ongoing research and development and operating expenses beyond the current cash runway.

Management Comments

• We are a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases.
• Leveraging the modularity of our FORCE platform, we are developing targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS.
• We believe these data support improvement in vHOT as an early indicator of clinical benefit with z-basivarsen in DM1 and its potential as an intermediate clinical endpoint for U.S. Accelerated Approval.
• Z-rostudirsen demonstrated best-in-class levels of dystrophin expression, exon skipping and percent dystrophin.
• We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future.
• We believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses, debt service obligations and capital expenditure requirements into the third quarter of 2027.

Industry Context

Dyne Therapeutics operates in the highly competitive biotechnology sector, specializing in rare genetically driven neuromuscular diseases. The company's FORCE platform aims to address critical delivery challenges to muscle and CNS tissues. The industry is characterized by intense competition from major pharmaceutical and biotech firms developing similar (oligonucleotide, gene therapy, gene editing) and different therapeutic approaches for conditions like DM1, DMD, FSHD, and Pompe disease. The regulatory environment is dynamic, with evolving requirements for clinical trials (e.g., Diversity Action Plans, accelerated approval pathways) and ongoing legal challenges to FDA approvals and drug pricing policies. The focus on rare diseases necessitates high reimbursement rates for commercial viability, and the industry faces increasing pressure on drug pricing from both governmental and private payers.

Comparison to Industry Standards

• For DMD, z-rostudirsen demonstrated 'best-in-class levels of dystrophin expression, exon skipping and percent dystrophin' compared to existing FDA-approved exon skipping drugs (e.g., EXONDYS 51, VYONDYS 53, AMONDYS 45 by Sarepta; VILTEPSO by Nippon Shinyaku Co. Ltd.) and the gene therapy ELEVIDYS by Sarepta.
• For DM1, z-basivarsen showed robust and sustained improvement in myotonia (vHOT) and muscle strength (QMT 20% improvement at 12 months), in a disease with no currently approved therapies for the underlying cause, positioning it favorably against other investigational therapies like those from Sanofi, AMO Pharma, Avidity, Pepgen, Arrowhead, ARTHEx Biotech, and Entrada Therapeutics.
• For FSHD, DYNE-302 preclinical data demonstrated robust and durable DUX4 suppression and functional benefit in a mouse model, in a disease with no currently approved therapies, competing with investigational products from Arrowhead, Avidity, Roche, University Hospital of Nice, Springbok Analytics, and Epicrispr Biotechnologies.
• For Pompe disease, DYNE-401 preclinical data showed clearance of glycogen in muscle and CNS, normalization of lysosomal size, and superior dose potency compared to GAA alone, supporting potential monthly dosing which is less frequent than approved enzyme replacement therapies (Myozyme/Lumizyme, Nexviazyme/Nexviadyme by Sanofi; Pombiliti + Opfolda by Amicus Therapeutics).

Management Changes

Corporate Governance

Legal Proceedings

• None.

Related Party Transactions

• Atlas Venture and related affiliated entities were beneficial owners of approximately 6.4% of the company's outstanding common stock as of September 30, 2025.
• The chairman of the company's board of directors is a partner at Atlas Venture.
• On January 27, 2025, Atlas Venture and related affiliated entities purchased 1,111,111 shares of common stock through the at-the-market offering program at a purchase price of $13.50 per share for aggregate gross proceeds of $15.0 million. The shares were purchased at the prevailing market price.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings and stock price volatility, but benefit from positive clinical data and Breakthrough Therapy Designations. No cash dividends are anticipated.
• Employees are impacted by the company's dependence on key personnel, competition for talent, and the use of stock-based compensation. Recent executive changes involved consulting agreements and forfeiture of awards.
• Future patients stand to benefit from potential new treatments for rare neuromuscular diseases (DM1, DMD, FSHD, Pompe) that could offer improved functional outcomes and quality of life if approved.
• Suppliers, CMOs, and CROs are critical partners, with new manufacturing services agreements securing capacity and committing to future fees, but also carry risks of disruptions.
• Creditors, specifically Hercules Capital, Inc., have a secured loan agreement with restrictive and financial covenants, with potential for default if conditions are not met.
• Regulatory bodies (FDA, EMA, MHLW Japan) are actively engaged in the review and designation processes for the company's product candidates, influencing development timelines and market access.

Next Steps

• Achieve full enrollment for the registrational expansion cohort of the ACHIEVE trial (DM1) by early Q2 2026.
• Initiate a Phase 3 clinical trial of z-basivarsen (DM1) in Q1 2026.
• Obtain data from the DELIVER trial registrational expansion cohort (DMD) in December 2025.
• Obtain data from the ACHIEVE trial registrational expansion cohort (DM1) in Q1 2027.
• Submit applications for U.S. Accelerated Approval for z-rostudirsen (DMD) in Q2 2026.
• Submit applications for U.S. Accelerated Approval for z-basivarsen (DM1) in early Q3 2027.
• Anticipate potential launch of z-basivarsen (DM1) in Q1 2028, assuming favorable data, priority review, and FDA approval.
• Continue to pursue approval pathways for z-basivarsen and z-rostudirsen outside of the U.S.
• Progress DYNE-302 (FSHD) through IND/CTA-enabling studies.
• Expand the portfolio through development efforts focused on rare skeletal muscle diseases, cardiac and metabolic muscle diseases, and CNS diseases.
• Obtain substantial additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances, and/or licensing arrangements to fund future operations.
• Compensate a CMO at least $25.5 million in fees through March 2027 as per a new master manufacturing services agreement.

Key Dates

Recommendation

Dyne Therapeutics has demonstrated promising clinical progress with its lead candidates, z-basivarsen and z-rostudirsen, both receiving Breakthrough Therapy Designations and showing positive long-term efficacy and safety data. The recent capital raises have significantly strengthened the company's liquidity, extending its cash runway into Q3 2027, which is crucial for a clinical-stage biotech. However, the company remains pre-revenue, with substantial and increasing operating losses, and will require significant additional funding in the future to bring products to market. The inherent risks of clinical development, regulatory approval, and commercialization in a highly competitive rare disease market are still very high. While the positive clinical and financial updates are encouraging, the long path to profitability and the need for future capital suggest a 'Hold' recommendation, acknowledging the potential upside from successful development balanced against the significant execution risks and ongoing cash burn.

Keywords

Neuromuscular disease, Clinical-stage, FORCE platform, DM1, DMD, FSHD, Pompe disease, Z-basivarsen, DYNE-101, Z-rostudirsen, DYNE-251, Breakthrough Therapy Designation, Orphan Drug Designation, Clinical trials, Accelerated Approval, Biotechnology, Drug development, Gene therapy, Oligonucleotide therapeutics, SEC filing, 10-Q